A Study of Cytisinicline for Vaping Cessation in Adult Smokers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-13

Study Completion Date

2023-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949

Smoking Cessation

COMPLETED PHASE3

Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

NCT06435221

Smoking Cessation Vaping Cessation

COMPLETED PHASE3

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT05206370

Smoking Cessation

COMPLETED PHASE3

Trial of Cytisine in Adult Smokers

NCT03709823

Smoking Cessation

COMPLETED PHASE2

Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion)

NCT05311085

Smoking Cessation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaping E-Cig Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo + Behavioral Support

one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

film-coated oral tablets containing matched placebo

Behavioral support

Intervention Type BEHAVIORAL

Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

Cytisinicline + Behavioral Support

one cytisinicline tablet PO TID plus behavioral support for 12 weeks

Group Type EXPERIMENTAL

cytisinicline

Intervention Type DRUG

film-coated oral tablets containing 3 mg cytisinicline

Behavioral support

Intervention Type BEHAVIORAL

Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cytisinicline

film-coated oral tablets containing 3 mg cytisinicline

Intervention Type DRUG

Placebo

film-coated oral tablets containing matched placebo

Intervention Type DRUG

Behavioral support

Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cytisine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects, age ≥ 18 years.
2. Test positive for cotinine using the Alere iScreen® OFD Cotinine Oral Fluid Screening Device (Positive testing at ≥ 30 ng/mL cotinine level).
3. Current daily nicotine-containing electronic cigarette usage as recorded in a screening diary for at least 7 consecutive days. Willing to bring the e-cigarette or nicotine device used to the clinical site so that the specific product type, flavor, and nicotine level can be documented.
4. Willing to initiate study treatment on the day after randomization and set a quit date within 7-14 days of starting treatment.
5. Willing to actively participate in the study's vaping cessation behavioral support provided throughout the study.
6. Able to fully understand study requirements, willing to participate, and comply with dosing schedule.
7. Sign the Informed Consent Form.

Exclusion Criteria

1. Currently smoking, or having smoked within 4 weeks prior to study randomization, any combustible cigarettes, other combustible tobacco products or non-combustible tobacco products (such as heat not burn products) (i.e., dual users).
2. Expired carbon monoxide (CO) levels ≥ 10 ppm, indicating recent combustible tobacco use.
3. More than 1 study participant in same household during the study treatment period.
4. Known hypersensitivity to cytisinicline or any of the excipients.
5. Positive urinary drugs of abuse screen determined within 28 days before the first dose of cytisinicline (Note: tetrahydrocannabinol (THC) is not part of the abuse screen).
6. Clinically significant abnormal serum chemistry or hematology values within 28 days of randomization (i.e., requiring treatment or monitoring).
7. Clinically significant abnormalities in 12-lead electrocardiogram determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e., requiring treatment or further assessment).
8. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
9. Current uncontrolled hypertension (blood pressure ≥ 160/100 mmHg).
10. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic; having suicidal ideation within the last 3 months (corresponding to question 4 or 5 on the Columbia - Suicide Severity Rating Scale \[C-SSRS\]); or current symptoms of moderate to severe depression (depression score ≥ 11 on the HADS) within the last 3 months.
11. Renal impairment defined as a creatinine clearance (CrCl) \< 60 mL/min (estimated with the Cockroft-Gault equation).
12. Hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.0 x the upper limit of normal (ULN).
13. Recent history or symptoms (within 4 weeks of randomization) of unstable respiratory disease (e.g., pneumonia, product-use associated lung injury or e-cigarette or vaping use-associated lung injury \[EVALI\], etc.)
14. Women who are pregnant or breast-feeding.
15. Male or female subjects of childbearing potential who do not agree to use acceptable methods of birth control starting at the time of consent, during the study treatment period, and continuing for one month after ending study treatment.
16. Participation in a clinical study with an investigational drug in the 4 weeks prior to study randomization.
17. Use of other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy \[NRT\]) in the 4 weeks prior to study randomization, any previous cytisinicline use, or planned use of these or other nicotine replacement medications during the study.
18. Any planned use during the study of combustible cigarettes or other nicotine-containing, non-vaping products (e.g., pipe tobacco, cigars, snuff, smokeless tobacco, hookah, ZYN pouches, etc).
19. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No